Skye Bioscience to Participate in SXSW Session on Obesity
Provided By GlobeNewswire
Last update: Feb 24, 2025
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.
Read more at globenewswire.com
